Publication | Closed Access

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer

Pancreatic CancerMedicineBotanical Formulation Phy906PharmacologyPharmacotherapyAdvanced Pancreatic CancerCancer TreatmentSecond-line TherapyOncologyCancer Research